PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
12.91M
Better than SAVA's estimated revenue of 0.
-2.58M
Worse than SAVA's estimated ebitda of 0.
-0.93
Worse than SAVA's estimated eps of 0.10.
-21.85M
Worse than SAVA's estimated net income of 4.19M.
-2.58M
Worse than SAVA's estimated ebit of 0.
478.53M
Worse than SAVA's estimated sg&a expense of 0.
Analyze DCF forecasts for the company and compare them with competitors.
1.03M
Better than SAVA's revenue of -1.80K.
-9.97%
Worse than SAVA's revenue growth rate of 0.00%.
-33.41M
Better than SAVA's ebitda of -74.94M.
-3243.20%
Worse than SAVA's ebitda margin of 4163611.11%.
-34.10M
Better than SAVA's ebit of -76.25M.
-3311.07%
Worse than SAVA's ebit margin of 4235888.89%.
699.00K
Better than SAVA's depreciation of 1.30M.
108.91M
Worse than SAVA's total cash of 201.01M.
10573.79%
Better than SAVA's cash as percentage of revenue of -11167500.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
10.13M
Worse than SAVA's accounts payable of 4.02M.
983.50%
Worse than SAVA's payables as percentage of revenue of -223166.67%.
-366.00K
Worse than SAVA's capital expenditure of -2.71M.
-35.53%
Better than SAVA's capex as percentage of revenue of 150666.67%.
4.99%
Better than SAVA's weighted average cost of capital (wacc) of 5.34%.
5.02%
Better than SAVA's cost of equity of 5.34%.
4.08%
Better than SAVA's cost of debt of 4.40%.
-0.23
Worse than SAVA's beta of -0.58.
30.07M
Better than SAVA's diluted shares outstanding of 41.93M.
1.57M
Worse than SAVA's total debt of 0.00.
49.31M
Worse than SAVA's total equity of 101.06M.
50.89M
Worse than SAVA's total capital of 101.06M.
3.09%
Worse than SAVA's debt weighting of 0.00%.
96.91%
Worse than SAVA's equity weighting of 100.00%.
-32.98M
Better than SAVA's ebiat of -72.47M.
-28.05M
Better than SAVA's unlevered free cash flow of -76.99M.
2.00%
Equal to SAVA's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than SAVA's net debt of -121.14M.
71.33M
Worse than SAVA's equity value of 112.01M.
2.37
Worse than SAVA's equity value per share of 2.67.